| 1 |
Guo B, Yuan Y. DROID: dose-ranging approach to optimizing dose in oncology drug development. Biometrics 2023. [PMID: 36807110 DOI: 10.1111/biom.13840] [Reference Citation Analysis]
|
| 2 |
Strohbehn GW, Lichter AS, Ratain MJ. US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action? J Clin Oncol 2023;:JCO2202049. [PMID: 36780590 DOI: 10.1200/JCO.22.02049] [Reference Citation Analysis]
|
| 3 |
Dehbi HM, O'Quigley J, Iasonos A. Controlled amplification in oncology dose-finding trials. Contemp Clin Trials 2023;125:107021. [PMID: 36526255 DOI: 10.1016/j.cct.2022.107021] [Reference Citation Analysis]
|
| 4 |
Araujo D, Greystoke A, Bates S, Bayle A, Calvo E, Castelo-Branco L, de Bono J, Drilon A, Garralda E, Ivy P, Kholmanskikh O, Melero I, Pentheroudakis G, Petrie J, Plummer R, Ponce S, Postel-Vinay S, Siu L, Spreafico A, Stathis A, Steeghs N, Yap C, Yap TA, Ratain M, Seymour L. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. Ann Oncol 2023;34:48-60. [PMID: 36182023 DOI: 10.1016/j.annonc.2022.09.158] [Reference Citation Analysis]
|
| 5 |
Murphy R, Halford S, Symeonides SN. Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective. Front Oncol 2023;13:1144056. [PMID: 36937434 DOI: 10.3389/fonc.2023.1144056] [Reference Citation Analysis]
|
| 6 |
Loeser AL, Gao L, Bardia A, Burkard ME, Kalinsky KM, Peppercorn J, Rugo HS, Carlson M, Cowden J, Glenn L, Maues J, McGlown S, Ni A, Padron N, Lustberg M. Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC). Breast Cancer Res Treat 2022;196:549-63. [PMID: 36198984 DOI: 10.1007/s10549-022-06755-5] [Reference Citation Analysis]
|
| 7 |
Strohbehn GW, Sankar K, Qin A, Kalemkerian GP. An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRAS G12C mutations. Expert Opin Pharmacother 2022. [PMID: 36217844 DOI: 10.1080/14656566.2022.2134777] [Reference Citation Analysis]
|
| 8 |
Strohbehn GW, Ratain MJ. Lorlatinib Exposed: A Far From Optimal Dose. Clin Pharmacol Ther 2022;111:1195-6. [PMID: 35394660 DOI: 10.1002/cpt.2579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Sproat MR, Hofherr ML, Devarakonda S. Successful use of Sotorasib in a Patient with End-Stage Renal Disease on Dialysis with Metastatic Lung Adenocarcinoma: A Case Report. Clinical Lung Cancer 2022. [DOI: 10.1016/j.cllc.2022.04.007] [Reference Citation Analysis]
|
| 10 |
Mayawala K, de Alwis D. Dose Finding in Oncology: What is Impeding Coming of Age? Pharm Res 2022. [PMID: 35474158 DOI: 10.1007/s11095-022-03263-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Krens SD, van Erp NP, Groenland SL, Moes DJAR, Mulder SF, Desar IME, van der Hulle T, Steeghs N, van Herpen CML. Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer. BMC Cancer 2022;22:228. [PMID: 35236333 DOI: 10.1186/s12885-022-09338-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Devlin SM, Iasonos A, O'Quigley J. Stopping rules for phase I clinical trials with dose expansion cohorts. Stat Methods Med Res 2022;31:334-47. [PMID: 34951338 DOI: 10.1177/09622802211064996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Moon H. FDA initiatives to support dose optimization in oncology drug development: the less may be the better. Transl Clin Pharmacol 2022;30:71. [DOI: 10.12793/tcp.2022.30.e9] [Reference Citation Analysis]
|
